- Details
- In this UroToday Journal Club Christopher Wallis and Zach Klaassen highlight a JAMA oncology publication entitled Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. VIABLE sought to evaluate the efficacy and safety of DCVAC/PCa plus...
|
- Details
- In this UroToday Journal Club Christopher Wallis and Zach Klaassen highlight a JAMA publication entitled the Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer. Symptom monitoring allows for the detection and treatment of symptoms, which may improve outcomes for cancer patients. The use of an electronic system to facilitate patient-reported o...
|
- Details
- In this UroToday Journal Club Chris Wallis and Zach Klaassen highlight a Journal of Nuclear Medicine publication entitled Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study . The RAdium LUtetium (RALU) study evaluated the feasibility of sequential al...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the results of the iROC trial, a JAMA publication titled the Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial . The iROC trial aimed to compare totally intracorporeal robotic assisted radical cy...
|
- Details
- In this UroToday Journal Club video presentation Christopher Wallis and Zachary Klaassen highlight a The Lancet Oncology publication titled MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. A study which aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patien...
|
- Details
- In this UroToday Journal Club video presentation Drs Christopher Wallis and Zachary Klaassen highlight a Journal of Nuclear Medicine publication titled Predictors of 18F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy which investigated the factors predicting scan positivity and disease location in patients with biochemical recurrence of pros...
|
- Details
- In this UroToday Journal Club video presentation Drs Christopher Wallis and Zachary Klaassen highlight a Lancet publication titled The Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy, the NRG RTOG 0534 SPPORT trial, an international, multicenter, randomized Phase III trial which was designed to determine whether incremental gains in pat...
|
- Details
- In this UroToday Journal Club presentation, Christopher Wallis and Zachary Klaassen highlight a JAMA Oncology publication led by Alex Bryant and Brent Rose titled The Association of PSA Screening Rates with Subsequent Metastatic Prostate Cancer Incidents at US Veterans Health Administration Facilities. PSA Screening is relatively controversial. Adopted in the United States in the 1990s it was asso...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the Journal of Nuclear Medicine publication entitled "mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in Post Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis." In low and middle-income countries, the treatment of prostate cancer is challenging due to a relatively advanced presentation of disease due to a lack of regu...
|
- Details
- In this UroToday Journal Club video presentation Christopher Wallis and Zachary Klaassen highlight the extended follow-up of overall survival and updated efficacy and safety in the CheckMate 9ER trial. The primary analysis of CheckMate 9ER showed nivolumab plus cabozantinib had superior progression-free survival, overall survival, and objective response over sunitinib in patients with previously u...
|
